We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M Turnover 15.38%
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
-3.43%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$222M
AUM Growth
–
Cap. Flow
+$260M
Cap. Flow %
117.26%
Top 10 Hldgs %
90.61%
Holding
16
New
16
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
IONQ icon
IonQ
IONQ
+$69.1M
2
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$37.7M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$31.5M
4
PMVP icon
PMV Pharmaceuticals
PMVP
+$23.9M
5
LABP icon
Landos Biopharma, Inc. Common Stock
LABP
+$19.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 65.12%
2 Technology 31.22%
3 Industrials 3.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IONQ icon
1
IonQ
IONQ
$13.9B
$69.3M 31.22%
+4,147,081
New +$69.1M
2021 Q4
0 quarters
CYT
2
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$28.1M 12.68%
+2,474,572
New +$37.7M
2021 Q4
0 quarters
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$26.4M 11.89%
+2,341,891
New +$31.5M
2021 Q4
0 quarters
PMVP icon
4
PMV Pharmaceuticals
PMVP
$69M
$22.9M 10.3%
+989,232
New +$23.9M
2021 Q4
0 quarters
DICE icon
5
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$13.6M 6.12%
+536,693
New +$15.7M
2021 Q4
0 quarters
LABP icon
6
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$8.77M 3.95%
+182,748
New +$19.2M
2021 Q4
0 quarters
EFTR icon
7
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$8.49M 3.83%
+41,028
New +$9.52M
2021 Q4
0 quarters
DTIL icon
8
Precision BioSciences
DTIL
$170M
$8.32M 3.75%
+37,464
New +$10.5M
2021 Q4
0 quarters
EVLV icon
9
Evolv Technologies
EVLV
$757M
$8.12M 3.66%
+1,820,866
New +$10.2M
2021 Q4
0 quarters
JBIO icon
10
Jade Biosciences
JBIO
$875M
$7.12M 3.21%
+17,250
New +$8.73M
2021 Q4
0 quarters
LENZ icon
11
LENZ Therapeutics
LENZ
$112M
$5.05M 2.28%
+58,044
New +$4.81M
2021 Q4
0 quarters
SERA icon
12
Sera Prognostics
SERA
$80.1M
$4.41M 1.99%
+641,361
New +$6.44M
2021 Q4
0 quarters
VOR icon
13
Vor Biopharma
VOR
$1.14B
$4.35M 1.96%
+18,736
New +$5.4M
2021 Q4
0 quarters
SPRO icon
14
Spero Therapeutics
SPRO
$65.8M
$3.99M 1.8%
+249,070
New +$3.96M
2021 Q4
0 quarters
RNAC icon
15
Cartesian Therapeutics
RNAC
$199M
$2.81M 1.27%
+28,751
New +$3.09M
2021 Q4
0 quarters
QTTB icon
16
Q32 Bio
QTTB
$238M
$233K 0.11%
+3,556
New +$345K
2021 Q4
0 quarters

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for OUP Management Company, which disclosed 16 positions worth $222M. Its ten largest holdings account for 91% of the portfolio.

Its largest position is IonQ: 4,147,081 shares worth $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, followed by Technology and Industrials.

  • OUP Management Company's largest Q4 2021 buy was IonQ: 4,147,081 shares worth $69.3M.
  • OUP Management Company's ten largest holdings make up 91% of its $222M portfolio in Q4 2021.
  • OUP Management Company disclosed 16 positions in Q4 2021, its first 13F filing on record.

Based on OUP Management Company's 13F filing for Q4 2021, filed 3 Feb 2022.